Posted by Michael Wonder on 10 Oct 2023
Lynparza (olaparib) accepted for use in Scotland as adjuvant treatment for patients with germline BRCA mutated HER2 negative high risk early breast cancer
9 October 2023 - First and only approved medicine in Scotland which targets germline (hereditary) BRCA mutations in early breast cancer (stage I-IIIA) previously treated with neo-adjuvant or adjuvant chemotherapy.
AstraZeneca today announced that Lynparza (olaparib) has been accepted for use within NHS Scotland by the SMC for use as monotherapy or in combination with endocrine therapy for the adjuvant treatment of adult patients with germline BRCA1/2 mutations, who have HER2 negative high risk early breast cancer previously treated with neo-adjuvant or adjuvant chemotherapy.
